2019 Lung Cancer Treatment Focused Research Grant Program
Christian Rolfo, MD, PhD, MBA
University of Maryland, Baltimore
Proactive monitoring of treatment-related adverse events through a mobile application in NSCLC patients treated with tyrosine kinase inhibitors: the “Empower Me” Digital Therapeutic Study
Targeted therapies have dramatically changed the therapeutic landscape of non-small cell lung cancer (NSCLC) over the past two decades leading to unprecedented results in selected patient populations. This novel therapeutic option is associated with a distinct toxicity profile that is, in many ways, different from toxicities commonly observed with conventional anticancer therapies. In selected cases, these toxicities can be severe and might affect compliance of the patients to the treatment regimen, including discontinuation of definitive therapy. In this study we will evaluate the potential impact of a proactive monitoring of treatment-related adverse events through a mobile application in NSCLC patients treated with tyrosine kinase inhibitors (TKIs). The APP will provide a simple, user-friendly interface to foster easy and efficient patient-provider communication. The implementation of an easy to use app and web–based communication will minimize dose limiting side effects with the use of TKIs in lung cancer. This will enable the patient to receive the anticancer therapy in the correct dose, frequency and without breaks in treatment.